EZH2 and diffuse large B-cell lymphoma: These genes are implicated in oncogenic pathways such as mTORC1 signaling, which has been linked to the development and drug resistance of EZH2 mutant DLBCL75, and their overexpression predicted a worse prognosis for DLBCL patients.